David Baker’s Technology Transfer and Advisory Roles
David Baker’s conflict of interest management plan is provided by UW and HHMI.
David Baker is a co-founder, shareholder, or advisor to the following companies. The first date on each line indicates the year of Company founding. (In parentheses are the dates & focus of David Baker’s involvement.) Founder = F, Advisor = A
ARZEDA Seattle WA 2009 (2009-present, F, A) Enzyme design engineering for agribusiness and fine chemicals.
PvP Biologics Seattle WA 2013 (2013-present, F, A) Designed enzyme therapeutic for celiac disease.
Cyrus Biotech: Seattle WA 2014 (2014-present, F, A) Cloud based software for biomolecular design.
Cue Biopharma Boston MA 2014 (2014-present, A) Biologic immunotherapies.
Icosavax Seattle WA 2017 (2017-present, F, A) Designed protein nanoparticle vaccines.
Neoleukin Therapeutics Seattle WA 2018 (2018-present, F, A) Designed proteins immunoncology.
Sana Biotechnology Seattle WA / San Francisco CA / Boston MA 2018 (2018-present, F, A) Creating and delivering engineered cells as medicine for patients.
Lyell Immunotherapeutics: Seattle WA / San Francisco CA 2018 (2018-present, F, A) Developing engineered T-cells designed to eliminate solid cancers.
A-Alpha Bio Seattle WA 2018 (2018-present, F, A) Developing a fundamentally new way of supporting safer drug discovery.
Companies licensing Baker lab patents or software:
PvP Biologics: Seattle / San Diego based company focused on the development of oral enzyme therapeutics for celiac disease, computationally designed enzymes that breakdown gluten in the stomach.
Cyrus Biotech: Seattle based company commercializing a user friendly Rosetta GUI for computational protein structure prediction and design – software as a service in the cloud solution for biotechnology and pharmaceutical research.
Icosavax: Seattle based company focused on development of a designed protein nanoparticle vaccine for respiratory syncytial virus (RSV) and other infectious diseases.
Neoleukin Therapeutics: Seattle based company developing an array of new proteins that activate the immune system to attack the worst types of cancer.
Lyell Immunotherapeutics: Seattle / San Francisco based company developing engineered T-cells designed to eliminate solid cancers.
Sana Biotechnology: Seattle / San Francisco / Boston based company creating and delivering engineered cells as medicine for patients.
A-Alpha Bio: Seattle based company developing a fundamentally new way of supporting safer drug discovery.